Data completeness
2/8 — Basic
RESNIBEN (cabozantinib) by R-Pharm US is and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of ret, met, vegfr-1, -2 and -3, kit, trkb, flt-3, axl, ros1, tyro3, mer, and tie-2.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESNIBEN (cabozantinib) is an oral small-molecule tyrosine kinase inhibitor targeting RET, MET, VEGFR, and multiple other receptor tyrosine kinases involved in oncogenesis and tumor progression. It is designed to address cancers driven by dysregulated kinase signaling and inhibit pathologic processes including metastasis, angiogenesis, and drug resistance. The exact approved indications remain under review, but cabozantinib has established clinical activity in RET-driven and MET-dysregulated malignancies.
Pre-Launch
As a pre-launch asset under R-Pharm US sponsorship, the commercial team is in build-phase, with significant opportunity for foundational brand positioning and early field infrastructure development.
Mechanism of Action
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Started Aug 2026
30 enrolled
Neurofibromatosis 1Plexiform Neurofibroma
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Started Mar 2026
16 enrolled
Clear Cell Renal Cell Carcinoma
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Started Mar 2026
254 enrolled
Advanced Renal Cell Carcinoma (RCC)
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Started Dec 2025
150 enrolled
Neuroendocrine Tumors
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Started Sep 2025
720 enrolled
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Worked on RESNIBEN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.